# US 2019/0241605 A1 · Hppk inhibitors useful as antibacterial agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241605 A1
- Document ID: US20190241605A1
- Status: Published application
- Kind: A1
- Application number: 16/340,493
- Filed: 2017-10-11
- Published: 2019-08-08
- Earliest claimed: 2016-10-11
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Servi
- Applicants: The United States of America, AS Represented By the Secretary, Department of Health and Human Servi
- Inventors: Xinhua Ji; Genbin Shi; Gary X. Shaw
- Web page: https://patentgrep.com/patent/US20190241605A1

## CPC

- C07H 19/167: with ribosyl as the saccharide radical
- A61P 31/04: Antibacterial agents
- C07D 475/04: with a nitrogen atom directly attached in position 2
- C07H 19/16: Purine radicals
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, and L1 are defined in the disclosure. These linked purine pterin inhibitors bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing the HPPK inhibitors and methods of treating a bacterial infection in a patient with one or more of the HPPK inhibitors of the disclosure are also provided.

## Claims

### Claim 1

A compound or pharmaceutically acceptable salt thereof of the formula:
wherein:
is a 5 or 6-membered heterocyclic ring;
X is nitrogen, —N(A5)-, —C(A6)-, or —C(A6A7)-;
A1 is hydrogen, oxo, amino, or aminoC1-C2alkyl;
A2 is absent, hydrogen, or C1-C2alkyl;
A3 is absent, or one or two substituents independently chosen from hydrogen, halogen, C1-C2alkyl, and C1-C2alkoxy;
A5 is hydrogen or C1-C4alkyl;
A6 and A7 are independently hydrogen, C1-C4alkyl, or C1-C4alkoxy;
R1 is C1-C4alkylene optionally substituted with hydroxyl, halogen, C1-C2alkyl, or oxo;
R2 is chosen from —NH—, —NHC(═O)—, —SH—, —S(═O)—, —S(═O)2—, —P(═O)—, and —P(═O)2—;
R3 is —N(R5—), —C1-C4alkyl)N(R5)—, or —C1-C4alkyl)C(O)N(R5)—, where R5 is alkyl substituted with —P(O)(OH)2, —OP(O)(OH)2, or —COOH;
R3 is a 5- or 6-membered heterocycloalkyl containing 1 or 2 heteroatoms independently chosen from N, O, and S, which 5- or 6-membered heterocycloalkyl is unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, —COOH, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; or
R3 is —(C1-C4alkyl)heterocycloalkyl; which heterocycloalkyl is a 5- or 6-membered heterocycloalkyl containing 1 or 2 heteroatoms independently chosen from N, O, and S, and is substituted with at least one —(C0-C4alkyl)P(O)(OH)2, —(C0-C4alkyl)OP(O)(OH)2, —(C0-C4alkyl)COOH, or —(C0-C4alkyl)C(═O)O(C1-C4alkyl) and optionally substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, —COOH, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy;
L1 is an alkylene linker having from 1 to 4 carbon atoms and containing 1 group selected from —O—, —NH—, —S—, —S(═O)—, —S(═O)2—, —S(═O)2NH—, —C(═O)NH—, —P(═O)—, and —P(═O)2—; and optionally containing 1 to 2 carbon-carbon double bonds, wherein L1 is unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, C1-C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy;
is a 5- or 6-membered monosaccharide ring; and
B1 and B2 are independently chosen from hydrogen, halogen, hydroxyl, amino, C1-C2alkyl, C1-C2alkoxy, mono- or di-C1-C2alkylamino, aminoC1-C2alkyl, C1-C2haloalkyl, and C1-C2haloalkoxy.

### Claim 2 (depends on 1)

A compound or salt of claim 1 of the formula
wherein
A2 is absent or hydrogen;
A3 is one or two substituents independently chosen from hydrogen and C1-C2alkyl; and
X is N or —C(A6)-.

### Claim 3 (depends on 1)

A compound or salt of claim 1 of the formula
wherein
A3 is one or two substituents independently chosen from hydrogen and C1-C2alkyl.

### Claim 4 (depends on 1)

A compound or salt of claim 1 of the formula
wherein:
A3 are each independently hydrogen, halogen, methyl, or methoxy.

### Claim 5 (depends on 1)

A compound or salt of claim 1 of the formula

### Claim 6 (depends on 1)

A compound or salt of claim 1 of the formula
where n is 0, 1, 2, or 3.

### Claim 7 (depends on 1)

A compound or salt of claim 1 of the formula
where n is 0, 1, 2, or 3.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

A compound or salt of claim 1, wherein
B1 and B2 are both hydrogen, and
is a 5-membered monosaccharide ring.

### Claim 10

(canceled)

### Claim 11 (depends on 10)

A compound or salt of claim 10 of the formula:
where n is 0, 1, 2, or 3.

### Claim 12 (depends on 10)

A compound of salt of claim 10 of the formula
where n is 0, 1, 2, or 3.

### Claim 13 (depends on 1)

A compound or salt of claim 1, wherein
R3 is a 5- or 6-membered heterocycloalkyl containing 1 or 2 heteroatoms independently chosen from N, O, and S, which —or 6-membered heterocycloalkyl is unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, —COOH, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy; or
R3 is —N(R5)—, —(C1-C4alkyl)N(R5)—, or —(C1-C4alkyl)C(O)N(R5)—, wherein R5 is C1-C4alkyl substituted with —P(O)(OH)2, —OP(O)(OH)2, or —COOH.

### Claim 14 (depends on 13)

A compound or salt of claim 13, wherein
R3 is piperidine or piperazine, which R3 is unsubstituted or substituted with one —COOH group; or
R3 is
—CH2CH2C(O)N(CH2P(O)(OH)2)—;
—CH2C(O)N(CH2P(O)(OH)2)—;
—CH2CH2N(CH2P(O)(OH)2)—; or
—N(CH2)P(O)(OH)2)—.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A compound or salt of claim 1, wherein
L1 is an alkylene linker having 1 to 43 carbon atom and containing 1 group selected from —S—, —S(═O)—, —S(═O)2—, —S(═O)2NH—, and —C(═O)NH—.

### Claim 18 (depends on 17)

A compound or salt of claim 17, wherein L1 is chosen from

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A compound or salt of claim 1, wherein
R3 is —(C1-C4alkyl)heterocycloalkyl; which heterocycloalkyl is a 5- or 6-membered heterocycloalkyl containing 1 or 2 heteroatoms independently chosen from N, O, and S, and is substituted with at least one —(C0-C4alkyl)P(O)(OH)2, —(C0-C4alkyl)OP(O)(OH)2, —(C0-C4alkyl)COOH, or —(C0-C4alkyl)C(═O)O(C1-C4alkyl), and optionally substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, —COOH, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy.

### Claim 21 (depends on 18)

A compound or salt of claim 18, wherein R3 is —(C1-C4alkyl)piperidine or —(C1-C4alkyl)piperazine, each of which piperidine or piperazine is unsubstituted or substituted with 1 or 2 —COOH groups.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A compound or salt thereof of claim 1, wherein the compound is chosen from

### Claim 24 (depends on 1)

A pharmaceutical composition comprising a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 1)

A method of treating a condition responsive to HPPK modulation, the method comprising providing a therapeutically effective amount of compound of claim 1 to a patient having a condition response to HPPK modulation.

### Claim 26 (depends on 25)

The method of claim 25, wherein the condition is a bacterial infection.
